相似文献
1
Japan's Conditional/Time-Limited Early Approval System in Regenerative Medicine: A Case Study of Rise and Falls of Autologous Skeletal Myoblast Sheets.
Clin Pharmacol Ther. 2025 May;117(5):1171-1174. doi: 10.1002/cpt.3562. Epub 2025 Jan 14.
2
Regulatory advancements in Japan's conditional and time-limited approval scheme for regenerative medical products: the first guidance on the approval scheme and the second review for full approval of the first conditional and time-limited approved cellular product, HeartSheet.
Cytotherapy. 2025 Jun;27(6):700-708. doi: 10.1016/j.jcyt.2025.02.010. Epub 2025 Mar 3.
3
Dark Clouds Looming Over Regenerative Medicine in Japan.
Stem Cells Dev. 2025 Apr;34(7-8):149-151. doi: 10.1089/scd.2025.0012. Epub 2025 Mar 6.
4
Too little, too soon: Japan's experiment in regenerative medicine deregulation.
Cell Stem Cell. 2023 Jul 6;30(7):913-916. doi: 10.1016/j.stem.2023.06.005.
5
Insurance systems and reimbursement concerning research and development of regenerative medicine in Japan.
Regen Med. 2017 Mar;12(2):179-186. doi: 10.2217/rme-2016-0124. Epub 2017 Feb 16.
6
The Roadmap to Approval under Japan's Two-Track Regulatory System: Comparing Six Regenerative Medical Products.
Cell Stem Cell. 2020 Oct 1;27(4):515-518. doi: 10.1016/j.stem.2020.09.003.
7
Conditional approval: Japan lowers the bar for regenerative medicine products.
Cell Stem Cell. 2015 Apr 2;16(4):353-6. doi: 10.1016/j.stem.2015.03.013.
8
Japan's patent issues relating to life science therapeutic inventions.
Expert Opin Ther Pat. 2014 Sep;24(9):953-7. doi: 10.1517/13543776.2014.944161. Epub 2014 Aug 4.
9
Autologous skeletal myoblast sheet implantation for pediatric dilated cardiomyopathy: A case report.
Gen Thorac Cardiovasc Surg. 2021 May;69(5):859-861. doi: 10.1007/s11748-020-01540-x. Epub 2020 Nov 7.
10
Regulatory brokerage: Competitive advantage and regulation in the field of regenerative medicine.
Soc Stud Sci. 2019 Jun;49(3):355-380. doi: 10.1177/0306312719850628.
引用本文的文献
1
Added Therapeutic Benefits of Top-Selling Drugs in Japan: A Cross-Sectional Study Using Health Technology Assessment.
Clin Transl Sci. 2025 Jun;18(6):e70243. doi: 10.1111/cts.70243.
本文引用的文献
1
Evaluating time to withdrawal of anti-cancer drug indications that received FDA's accelerated approval.
QJM. 2025 Jan 1;118(1):3-4. doi: 10.1093/qjmed/hcae115.
2
Nationalism in Japanese media coverage of domestic pharmaceutical products.
Lancet. 2023 Nov 18;402(10415):1832-1833. doi: 10.1016/S0140-6736(23)01284-9.
3
Association Between Preapproval Confirmatory Trial Initiation and Conversion to Traditional Approval or Withdrawal in the FDA Accelerated Approval Pathway.
JAMA. 2023 Mar 7;329(9):760-761. doi: 10.1001/jama.2023.0625.
4
Japan's conditional early approval program for innovative cancer drugs: Comparison of the regulatory processes with the US FDA and the EMA.
Cancer Cell. 2021 Sep 13;39(9):1165-1166. doi: 10.1016/j.ccell.2021.07.008. Epub 2021 Aug 5.
5
Downgrading of regulation in regenerative medicine.
Science. 2019 Aug 16;365(6454):644-646. doi: 10.1126/science.aax6184.
6
First Approval of Regenerative Medical Products under the PMD Act in Japan.
Cell Stem Cell. 2016 Apr 7;18(4):434-5. doi: 10.1016/j.stem.2016.03.011.
7
Stem the tide.
Nature. 2015 Dec 10;528(7581):163-4. doi: 10.1038/528163b.
8
Safety and Efficacy of Autologous Skeletal Myoblast Sheets (TCD-51073) for the Treatment of Severe Chronic Heart Failure Due to Ischemic Heart Disease.
Circ J. 2015;79(5):991-9. doi: 10.1253/circj.CJ-15-0243.
Zotero 插件